← Leaderboards
Peter M. Pushko
Medigen, Inc.
$8,622,434
Attributed
$10,582,139
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,582,139 · 11
By mechanism
R01$5,445,787 · 2
U01$1,876,310 · 1
R44$1,624,180 · 1
R43$1,371,691 · 5
R03$174,300 · 1
N43$89,871 · 1
Top collaborators
- Igor S. Lukashevich6 shared
Others in their field
Top investigators on “Technology”
- David Heimbrook · Leidos Biomedical Research, Inc.$995,338,451
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$606,570,095
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Richard K. Wilson · Washington University$441,856,657
Research focus
TechnologyImmunogenicityVaccinationVirusVaccinesSafetyGeneticDesignProductionEvaluationPathogenMutationNational Institute Of Allergy And Infectious DiseaseNeutralizing AntibodyImmunityImmune ResponseUnited States National Institutes Of HealthCollaborationsRecombinantsImmunizationCategoriesDisease OutbreaksEpidemicAlphavirus
Grant awards (26)
Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults$562,567
U01 · FY2024 · AI · contact PI
Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults$604,508
U01 · FY2023 · AI · contact PI
Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults$709,235
U01 · FY2022 · AI · contact PI
Novel Chikungunya vaccine with rearranged genome$120,042
R43 · FY2021 · AI · contact PI
Novel Chikungunya vaccine with rearranged genome$120,759
R43 · FY2020 · AI · contact PI
Multivalent emergency vaccine against pandemic influenza$95,379
R43 · FY2019 · AI · contact PI
Multivalent emergency vaccine against pandemic influenza$95,379
R43 · FY2018 · AI · contact PI
Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II$812,615
R44 · FY2017 · AI · contact PI
Broad-Range VLP Vaccine Against H5N1 Influenza$383,409
R01 · FY2017 · AI · contact PI
Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II$811,565
R44 · FY2016 · AI · contact PI
Broad-Range VLP Vaccine Against H5N1 Influenza$392,210
R01 · FY2016 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$727,652
R01 · FY2015 · AI
Broad-Range VLP Vaccine Against H5N1 Influenza$400,757
R01 · FY2015 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$727,652
R01 · FY2014 · AI
Broad-Range VLP Vaccine Against H5N1 Influenza$350,000
R01 · FY2014 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$773,368
R01 · FY2013 · AI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$822,732
R01 · FY2012 · AI
Novel DNA-Launched Attenuated Vaccine for VEE Virus$300,000
R43 · FY2012 · AI · contact PI
A novel DNA-launched live attenuated Chikungunya vaccine$87,150
R03 · FY2012 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$745,933
R01 · FY2011 · AI
Novel DNA-Launched Attenuated Vaccine for VEE Virus$300,000
R43 · FY2011 · AI · contact PI
Trivalent Arenaviral Vaccine Based on Virus-Like Particle Vectors (VLPVs)$222,146
R43 · FY2011 · AI · contact PI
Development of New Bivalent Cross-Protective Arenaviral Vaccines$122,074
R01 · FY2011 · AI
Infectious DNA (i-DNA) Vaccine for Yellow Fever$117,986
R43 · FY2011 · AI · contact PI
A novel DNA-launched live attenuated Chikungunya vaccine$87,150
R03 · FY2011 · AI · contact PI
SBIR TOPIC 255$89,871
N43 · FY2009 · CA · contact PI